Read More

Daré Bioscience Announces Publication In Contraception Of Efficacy And Safety Findings From A Pre-Pivotal Postcoital Test Study Of Ovaprene: An Investigational Hormone-Free Monthly Intravaginal Contraceptive

Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 womenPivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrollingOvaprene has the potential to be the

DARE

Read More

Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize TPM-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist; Harmony Will Pay Bioprojet An Upfront License Fee Of $25.5M For The Exclusive Right

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor

HRMY

Read More

Sight Sciences Announces The Publication Of Large-Scale, Real-World MIGS Study Demonstrating The Aqueous Outflow Restorative Procedure With OMNI Surgical System Technology Is Effective At Lowering Both IOP And IOP Reducing Medications At 2 Years In Pat…

Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and

SGHT

Read More

Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies

Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections and strategic initiatives, Amphastar aims to capitalize on emerging opportunities in the endocrinology sector for continued growth.

AMPH